CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.9500
+0.0600 (+1.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.8900
Open3.8600
Bid3.1500 x 1000
Ask7.0000 x 800
Day's Range3.7700 - 3.9800
52 Week Range3.2200 - 13.9100
Volume69,870
Avg. Volume93,116
Market Cap115.841M
Beta (3Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-1.7060
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006, both as monotherapies and in combination with other agents and each other, positioning Corvus as a leader in the development of medicines that modulate the adenosine pathway,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. Continued enrollment of up to 50 patients with renal cell cancer (RCC) in an amended Phase 1b/2 clinical trial evaluating CPI-444 administered alone and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody.

  • GlobeNewswirelast month

    Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

    BURLINGAME, Calif., March 05, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization.

  • GlobeNewswire2 months ago

    Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and clinical results from its two lead programs that target the adenosine pathway, CPI-444, an adenosine A2A receptor antagonist, and CPI-006, an anti-CD73 antibody. The data were presented by Stephen Willingham, Ph.D., Senior Scientist at Corvus, at the Immuno-Oncology 360° Conference in New York during the “Discovery & Preclinical Science Plenary” session, which focused on tumor microenvironment changing technologies, pegylated cytokines and additional discovery and preclinical data. Dr. Willingham’s presentation, titled “Blockade of the Adenosine Pathway: Preclinical, Translational and Clinical Studies with CPI-444, an A2A Receptor Antagonist for Cancer Treatment,” reviewed gene expression data of an adenosine gene signature recently announced by Corvus (or AdenoSig), in patients with renal cell carcinoma (RCC) who are participating in Corvus’ ongoing Phase 1/1b study of CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.

  • GlobeNewswire3 months ago

    Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference

    BURLINGAME, Calif., Jan. 30, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire3 months ago

    Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S. Grais, M.D., J.D., to the Company’s Board of Directors and Mehrdad Mobasher, M.D., M.P.H., as Vice President and Chief Medical Officer, effective immediately. Dr. Grais has more than 20 years of experience with emerging companies in the biopharmaceutical industry. As a member of Corvus’ Board of Directors, she is replacing Peter Moldt, Ph.D., who has served as a director since January 2015 and resigned his position.

  • Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year?
    Simply Wall St.3 months ago

    Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • GlobeNewswire3 months ago

    Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

    Study results indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity. Based on these data, Corvus plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in early 2019.

  • GlobeNewswire3 months ago

    Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it has initiated patient enrollment in the second arm of its ongoing Phase 1/1b dose-escalation study. This arm is evaluating CPI-006, a humanized monoclonal antibody directed against CD73, in combination with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor. The Phase 1/1b study is currently enrolling patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and other cancers who have failed standard therapies.  The first arm of the study is evaluating CPI-006 as a single agent and has dosed patients in several cohorts of escalating doses.

  • Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
    Zacks4 months ago

    Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher

    Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Sarepta Stock More Than Doubles This Year So Far: Here's Why
    Zacks5 months ago

    Sarepta Stock More Than Doubles This Year So Far: Here's Why

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

  • GlobeNewswire5 months ago

    Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference

    BURLINGAME, Calif., Nov. 12, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire5 months ago

    Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced updated clinical and biomarker data from ongoing Phase 1/1b studies of its lead programs, CPI-444 and CPI-006. Updated results from its Phase 1/1b clinical trial of CPI-444 in patients with treatment-refractory renal cell carcinoma (RCC) demonstrated an overall survival (OS) of 88 percent at more than 20 months follow-up with CPI-444 administered in combination with atezolizumab. The clinical data were presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting in Washington, D.C., by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

  • GlobeNewswire5 months ago

    Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018

    Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif., Nov. 05, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a.

  • Associated Press6 months ago

    Corvus: 3Q Earnings Snapshot

    The Burlingame, California-based company said it had a loss of 36 cents per share. Corvus shares have dropped 21 percent since the beginning of the year. The stock has declined 41 percent in the last 12 ...

  • GlobeNewswire6 months ago

    Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. This includes biomarker data for CPI-444 that our team presented at the ESMO 2018 Congress on October 22, 2018.

  • Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks7 months ago

    Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Associated Press9 months ago

    Corvus: 2Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 40 cents. Corvus shares have fallen 9 percent since the beginning of the year. In the final minutes of trading on Thursday, ...